ArticleMicrobiologyOpen2026
Antioxidant and Antibacterial Activities of Secondary Metabolites Produced by Streptomyces Isolates Against Extended-Spectrum β-Lactamase-Producing Bacteria.
Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacteria pose a severe therapeutic challenge globally. Streptomyces remain one of the most prolific natural sources of antibacterial and antioxidant secondary metabolites, yet their activity against ESBL-producing pathogens remains under-explored. Soil-derived Streptomyces isolates were screened for bioactivity, and the most potent strain (SM7) was identified by 16S rRNA sequencing. Secondary metabolites were extracted using ethyl-acetate and evaluated for antibacterial activity against ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae using agar diffusion, MIC, and MBC assays. Antioxidant activity was assessed using DPPH and ABTS assays, while GC-MS and molecular docking were employed to identify and characterize bioactive compounds. Streptomyces sp. SM7 exhibited strong antibacterial activity, producing inhibition zones of 21.4 ± 0.6 mm, 19.2 ± 0.4 mm, and 17.6 ± 0.5 mm against ESBL-producing E. coli, K. pneumoniae, and E. cloacae, respectively. MIC values ranged from 62.5 to 250 µg/mL, with bactericidal MBC/MIC ratios of 2. The extract showed potent antioxidant activity with DPPH and ABTS IC₅₀ values of 48.9 µg/mL and 61.4 µg/mL, respectively. GC-MS identified 18 bioactive compounds, with 2,4-di-tert-butylphenol (18.6%) as the major constituent, which exhibited a docking affinity of -7.1 kcal/mol against bacterial DHFR. Streptomyces sp. SM7 produces phenolic- and fatty-acid-rich metabolites with potent bactericidal and antioxidant activities against ESBL-producing pathogens, highlighting its promise as a natural source of next-generation antimicrobial agents. These findings support Streptomyces sp. SM7 as a promising lead for downstream purification, mechanism-guided optimization, and future drug-development efforts targeting difficult-to-treat ESBL-producing Enterobacterales.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.